Share Search
Visit the Share Search
Shield taps Hans-Peter Rudolf as its new finance chief
22nd Mar 2021 08:18
(Sharecast News) - Commercial-stage pharmaceuticals company Shield Therapeutics announced on Monday that Hans-Peter Rudolf was joining its senior executive team as chief financial officer, with immediate effect.
The AIM-traded firm said Swiss national Rudolf was bringing "extensive" international experience, particularly in the United States.
It said he is a US Certified Public Accountant, having started his career in 1991 in public practice with Deloitte in Cleveland, Ohio, before moving back to Switzerland in 1996 to join EY, where he became a partner in 2001.
In 2003 he moved back to Cleveland with EY as an audit partner, and then between 2006 to 2010 as an audit partner with Crowe, the eighth-largest global accounting network.
It said that in 2011, Rudolf left public practice to become head of group accounting at Cofra Group, a privately-held Swiss conglomerate with activities in retail, real estate and investment, employing more than 50,000 people globally.
In 2017, he was appointed as chief financial officer at Vicarius Pharma, a start-up company offering research-driven pharma and biotech companies a platform to build a European commercial organisation, to market and sell their assets through long-term license and partnership agreements.
"I am delighted that Hans-Peter has agreed to join Shield at this point in the group's evolution," said chief executive officer Tim Watts.
"His experience in both public practice and commercial companies and his US experience will be invaluable to Shield, particularly as we scale up activities in the US."
At 0902 GMT, shares in Shield Therapeutics were down 1.11% at 33.42p.
The AIM-traded firm said Swiss national Rudolf was bringing "extensive" international experience, particularly in the United States.
It said he is a US Certified Public Accountant, having started his career in 1991 in public practice with Deloitte in Cleveland, Ohio, before moving back to Switzerland in 1996 to join EY, where he became a partner in 2001.
In 2003 he moved back to Cleveland with EY as an audit partner, and then between 2006 to 2010 as an audit partner with Crowe, the eighth-largest global accounting network.
It said that in 2011, Rudolf left public practice to become head of group accounting at Cofra Group, a privately-held Swiss conglomerate with activities in retail, real estate and investment, employing more than 50,000 people globally.
In 2017, he was appointed as chief financial officer at Vicarius Pharma, a start-up company offering research-driven pharma and biotech companies a platform to build a European commercial organisation, to market and sell their assets through long-term license and partnership agreements.
"I am delighted that Hans-Peter has agreed to join Shield at this point in the group's evolution," said chief executive officer Tim Watts.
"His experience in both public practice and commercial companies and his US experience will be invaluable to Shield, particularly as we scale up activities in the US."
At 0902 GMT, shares in Shield Therapeutics were down 1.11% at 33.42p.